arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Capricor Therapeutics, Inc.

CAPR Health Care Biotechnology: Pharmaceutical Preparations
$9.35
▼ -0.5% Today
as of Sep 4, 16:47 ET
Last 30 days +34.29% Jul 27 → Sep 04
$3.35 $5.15 $6.96 $8.76 $10.56 Jul 27 Aug 04 Aug 12 Aug 19 Aug 27 Sep 04
Open
$9.40
High
$9.81
Low
$9.26
Volume
$3M
Avg Vol
$3M
Mkt Cap
$397M
P/E (TTM)
—
Beta
—
52w High
$40.37
52w Low
$2.96
Div Yield
—
Shares Out
$58M

Recent Press Releases & News last 60 days · 25 items

Sep 5 · 00:44 Insider Monkey
Could New Long-Term Data Support Capricor’s Duchenne Therapy?
Sep 1 · 18:13 MT Newswires
Capricor Therapeutics Shares Rise After Piper Sandler Upgrade
Sep 1 · 10:55 InvestorsHub
Capricor Therapeutics shares rise 2.5% following August FDA update
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$2.96
$40
17% of range
Avg surprise (last 3)
-28.9%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
310%
EM ±12.9% · $10 · Sep 4

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.70$-0.59$-0.47$-0.36$-0.25 Actual $-0.31Actual $-0.29Actual $-0.25Actual $-0.31Actual $-0.35Actual $-0.38Actual $-0.53Est $-0.33Actual $-0.57Est $-0.48Actual $-0.54Actual $-0.59Est $-0.55Actual $-0.70 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-41M$-30M$-19M$-8M$2M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.70 — — — — financials
Tue May 12, 2026Mar/2026 $-0.59 $-0.55 -7.3% -11.3% -1.2% earnings
Tue Sep 30, 2025Sep 2025 $-0.54 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.57 $-0.48 -18.8% — — earnings
Tue May 13, 2025Mar/2025 $-0.53 $-0.33 -60.6% — +2.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.38 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.35 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.31 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.25 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.29 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.31 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———————$2M
Cost of revenue————————
Gross profit————————
Operating income$-43M$-37M—$-26M$-28M$-25M—$-13M
Net income$-41M$-34M—$-25M$-26M$-24M—$-13M
EPS (diluted)$-0.70$-0.59—$-0.54$-0.57$-0.53—$-0.38

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$21M$105M$288M$20M$23M$29M$11M$68M
Inventory————————
Total current assets$242M$283M$323M$101M$124M$146M$163M$86M
Total assets$369M$326M$356M$126M$134M$154M$170M$93M
Long-term debt————————
Total liabilities$123M$48M$50M$43M$29M$26M$25M$25M
Total equity$246M$279M$306M$84M$105M$128M$145M$68M

Implied volatility — last 90 days

81%213%344%475%607% Jun 07 — IV 107% · EM ±14.9%Jun 08 — IV 130% · EM ±17.2%Jun 09 — IV 116% · EM ±14.6%Jun 10 — IV 97% · EM ±11.4%Jun 11 — IV 82% · EM ±9.1%Jun 12 — IV 99% · EM ±10.1%Jun 15 — IV 164% · EM ±11.9%Jun 16 — IV 148% · EM ±8.7%Jun 17 — IV 116% · EM ±4.8%Jun 19 — IV 82% · EM ±18.1%Jun 22 — IV 95% · EM ±19.8%Jun 23 — IV 99% · EM ±20.2%Jun 24 — IV 102% · EM ±20.3%Jun 25 — IV 93% · EM ±18.3%Jun 26 — IV 116% · EM ±22.2%Jun 29 — IV 109% · EM ±19.4%Jun 30 — IV 113% · EM ±19.4%Jul 01 — IV 123% · EM ±20.5%Jul 02 — IV 124% · EM ±20.0%Jul 03 — IV 128% · EM ±20.0%Jul 06 — IV 110% · EM ±15.3%Jul 07 — IV 184% · EM ±24.3%Jul 08 — IV 126% · EM ±15.8%Jul 09 — IV 156% · EM ±18.4%Jul 10 — IV 203% · EM ±22.4%Jul 13 — IV 120% · EM ±10.0%Jul 14 — IV 127% · EM ±9.2%Jul 15 — IV 424% · EM ±25.1%Jul 16 — IV 607% · EM ±25.4%Jul 20 — IV 331% · EM ±78.2%Jul 21 — IV 316% · EM ±73.5%Jul 22 — IV 327% · EM ±74.8%Jul 23 — IV 312% · EM ±70.1%Jul 24 — IV 334% · EM ±73.9%Jul 27 — IV 396% · EM ±82.7%Jul 28 — IV 348% · EM ±71.2%Jul 30 — IV 297% · EM ±58.2%Jul 31 — IV 256% · EM ±49.1%Aug 03 — IV 294% · EM ±52.1%Aug 04 — IV 232% · EM ±40.0%Aug 05 — IV 262% · EM ±43.7%Aug 06 — IV 246% · EM ±39.8%Aug 07 — IV 278% · EM ±43.4%Aug 10 — IV 300% · EM ±41.6%Aug 11 — IV 284% · EM ±37.5%Aug 12 — IV 305% · EM ±38.2%Aug 13 — IV 356% · EM ±42.1%Aug 14 — IV 307% · EM ±34.0%Aug 17 — IV 341% · EM ±28.5%Aug 18 — IV 360% · EM ±26.1%Aug 19 — IV 472% · EM ±27.9%Aug 20 — IV 460% · EM ±19.2%Aug 24 — IV 116% · EM ±24.3%Aug 25 — IV 117% · EM ±23.9%Aug 26 — IV 127% · EM ±25.5%Aug 28 — IV 306% · EM ±33.9%Aug 31 — IV 133% · EM ±11.1%Sep 01 — IV 199% · EM ±14.4%Sep 02 — IV 137% · EM ±8.1%Sep 03 — IV 310% · EM ±12.9%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in